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ABSTRACT
Introduction: Complementary and Alternative Medicine (CAM) include a wide 
range of products (herbs, vitamins, minerals, and probiotics) and medical practices, 
developed outside of the mainstream Western medicine. Patients with cancer are 
more likely to resort to CAM first or then in their disease history; the potential side 
effects as well as the costs of such practices are largely underestimated.
Patients and method: We conducted a descriptive survey in five Italian hospitals 
involving 468 patients with different malignancies. The survey consisted of a forty-
two question questionnaire, patients were eligible if they were Italian-speaking 
and receiving an anticancer treatment at the time of the survey or had received an 
anticancer treatment no more than three years before participating in the survey.
Results: Of our patients, 48.9% said they use or have recently used CAM. The 
univariate analysis showed that female gender, high education, receiving treatment 
in a highly specialized institute and receiving chemotherapy are associated with 
CAM use; at the multivariate analysis high education (Odds Ratio, (OR): 1.96 95% 
Confidence Interval, CI, 1.27-3.05) and receiving treatment in a specialized cancer 
center (OR: 2.75 95% CI, 1.53-4.94) were confirmed as risk factors for CAM use.
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Conclusion: Roughly half of our patients receiving treatment for cancer use CAM. 
It is necessary that health professional explore the use of CAM with their cancer 
patients, educate them about potentially beneficial therapies in light of the limited 
available evidence of effectiveness, and work towards an integrated model of health-
care provision.
INTRODUCTION
According to the National Center for 
Complementary and Integrative Health, USA, the 
Complementary and Alternative Medicine (CAM), include 
a wide range of products, such as herbs (also known as 
botanicals), vitamins, minerals, and probiotics, and 
medical practices, such as acupuncture or magneto-therapy, 
which are outside of the mainstream Western medicine. 
Such practices or substances are defined ‘alternative’ 
when they are used in place of conventional medicine 
and ‘complementary’ when they are used together with 
conventional medicine [1]. The interpretation provided by 
Ernst E et al. (UK), is much more complex and defines 
CAM as ‘diagnosis, treatment and/or prevention which 
complements mainstream medicine by contributing 
to a common whole, satisfying a demand not met by 
orthodoxy, or diversifying the conceptual framework 
of medicine’ [2]. Both the definitions are correct and 
one does not exclude the other; indeed the use of such 
unconventional substances/treatments, which has always 
been very common among the eastern populations and 
in the developing countries, is acquiring more and more 
popularity also in the western world for multiple reasons. 
In the US, the use of CAM is constantly increasing with 
the largest practice being among the non-hispanic whites 
[3] and in the rural areas (rate of use up to 63%) compared 
with the cities [4, 5]; in terms of geographic areas the 
highest rate of use was observed in the Mountain Regions 
and in New Mexico [6]. A systematic review published 
in 2013 by Posadzki P et al. highlighted the difficulties 
of identifying reliable data about the prevalence of CAM 
due to the poor methodological quality of most studies 
and the ambiguity of the definition of CAM; however, the 
authors concluded that the average one-year prevalence 
is 41.1% and the average lifetime prevalence is 58.1% 
[7]. A European survey conducted by Molassiotis A. 
et al., demonstrated that the use of CAM in the EU is 
about 35.9% of the total patient population. The use of 
CAM has increased steadily over the past 15 years or so; 
undoubtedly it has gained medical, economic and social 
importance [8]. Patients with cancer are more likely to 
resort to CAM, first or then in their disease history, for 
a wide range of reasons; firstly, the unfavorable outcome 
in a relevant percentage of cases leads patients to ‘leave 
no stone unturned’; secondly, the heavy toxicities, often 
associated with the traditional antineoplastic therapies, 
induce them to look for something different from the 
prescribed therapy or more simply for substances 
presumed to reduce the side effects from such therapies 
[9]. Nevertheless the literature about CAM prevalence in 
cancer patients is not particularly rich, especially if we 
consider only the European papers, and the prevalence is 
probably underestimated. Many patients do not declare 
that they engage in this practice, on the one hand because 
they undervalue the relevance of the products they take, 
considering them ‘natural’, unable to interact with the 
conventional drugs and devoid of side effects, and, on the 
other hand, because they are somehow reluctant to admit 
the use of an unconventional treatment, worrying that such 
behavior may be interpreted as reflecting a loss of trust in 
their oncologist and the treatment he/she has prescribed. 
Furthermore most clinicians are unfamiliar with these 
kinds of treatments [10] and hence do not pay enough 
attention to this aspect of the anamnesis at the time of the 
visit; usually they do not explicitly ask about this topic, as 
they do for all other health matters such as comorbidity or 
conventional drugs [9, 11]. The available studies report 
that the prevalence of CAM use among cancer patients 
is in the range of 12.5-73% [12–15]. This enormous 
variability is, at least partially, justified by the inconsistent 
definition of CAM, with some authors including only 
herbal medications, while some others considering also 
including dietary supplements and unconventional medical 
practices (massages, acupuncture). The aim of this study 
was to assess the use of CAM across a number of Italian 
cancer hospitals, using the same measurement tool and the 
same definition of CAM and trace the “identikit” of typical 
cancer patient “CAM-users”.
RESULTS
The five hospitals that participated in the study 
provided a total of 468 subjects that were eligible for 
clinical considerations and statistical analysis. Table 1  
summarizes the baseline characteristics of the population.
Socio-demographic and clinical characteristics of 
the sample
With respect to demographics, the cohort was well 
balanced between males and females (48.9% vs. 51.1%), 
the median age at the time of diagnosis of cancer was 
57 years old, while the age at the time of the survey was 
between 40 and 70 years of age for more than half of 
the patients. The educational level was low (primary or 
secondary school) for 38%, high (high school, degree or 
higher) for 62%; the Italian region of origin was the South 
or the Islands for 47.6%, and the Centre or North for the 
remaining 52.4%. Most patients received their treatment at 
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Table 1: Baseline and demographics
Baseline and Demographics n=468
SEX n (%)
 male 229(48.9)
 female 239(51.1)
Median Age at diagnosis (range) 57 (19-82)
Age  
 < 40 23 (4.9)
 40 – 70 245 (52.4)
 > 70 200 (42.7)
EDUCATION  
 Elementary/middle (< 8 ys) 178 (38)
 High/degree (> 8 ys) 290 (62)
ORIGIN  
 Centre/North 245 (52.4)
 South/Islands 223 (47.6)
HOSPITAL  
 Cancer centre 325 (69.4)
 Peripheral hospital/clinic 143 (30.6)
PRIMARY TUMOUR  
 Lung 222 (47.4)
 Breast 78 (16.7)
 Colorectal 56 (12)
 Gastric/Pancreas/HCC/Biliary tract 23 (4.9)
 Uro-Gynecology 26 (5.6)
 Other 63(13.5)
STAGE  
 Early 100 (21.4)
 Locally advanced 114 (24.4)
 Metastatic 254 (54.3)
TREATMENT  
 AC only 238 (50.9)
 Multimodal 154 (32.9)
 Surgery only 25 (5.3)
 Surgery + AC 51 (10.9)
ANXIETY  
 Never 314 (67.1)
 Sometimes 82 (17.5)
 Often 72 (15.4)
PAIN  
 No 318 (67.9)
 Yes 150 (32.1)
PS  
 1-2 346 (73.9)
 > 2 69 (14.7)
 0 53 (11.3)
Legend: ys, years; AC, Chemotherapy; Multimodal: surgery +chemotherapy + hormone therapy/radiation or both; PS, 
Performance Status.
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a cancer center rather than at a peripheral hospital or clinic 
(69.4% vs 30.6%). With respect to disease characteristics, 
the primary cancer site was lung (47.4%), followed by 
breast (16.7%), and colorectal (12%). Most patients had a 
metastatic (54.3%), or locally-advanced (24.4%), disease; 
the treatment received was based on AC alone in the 
50.9% of the cases, a good percentage, 32.9%, received 
a multimodal treatment (surgery plus AC plus hormone 
therapy and/or radiotherapy), only 25 (5.3%) had only 
surgery. Most subjects declared that they did not anxiety 
disorders, 67.1%, and did not complain of chronic pain, 
67.9%. The ECOG Performance Status was 1 or 2 in most 
cases (73.9%).
Information about CAM
Table 2 shows the answers about the general feeling 
with respect to conventional medicine and CAM: More 
than 90% thought they had a good/excellent awareness 
about the disease and the therapies received. Almost all the 
interviewed declared that they have trust in conventional 
medicine and oncological treatments, 94.2% and 95% 
respectively, though roughly 50% expected to be treated 
rather than cured and there was a relevant percentage, 
32%, admitting to be concerned about financial 
speculation around anticancer drugs. Of the population 
surveyed, 75.6% said they knew what CAM was, but only 
27.6% were aware of the difference between alternative 
and complementary medicine. Among the patients aware 
of what CAM was (354), most had heard about it from the 
media, friends, or other patients, and only the 5.9% from 
a doctor (Figure 1). Eight patients (3.5%) reported side-
effects from the CAM therapy assumption. Most seemed 
to be transient side-effects and they were all related to 
ingesting herbs or minerals. These side effects included 
stomach aches (two with aloe, one with vitamin C and 
two with high consumption of green tea) gastric upset 
and nausea from using unspecified herbs (two patients), 
and diarrhoea with aloe (one patient). The most frequent 
answer to the question ‘what CAM is?’ was ‘medicines 
to reduce AC toxicities’ followed by ‘supplements’ and 
‘overall’, which meant ‘all the above’. Of the subjects, 
48.9% (229) answered ‘yes’ to the direct question ‘have 
you ever used any CAM?’. Table 3  shows the distribution 
of CAM users by type, prescriber, cost, and satisfaction 
with the product. Interestingly, the use of CAM mainly 
derived from an auto-prescription (67%), most patients 
were not aware of the potential side effects, the substance 
was bought by the patient himself at an average cost of 
between 100 and 300 euros, the duration of the treatment 
was less than one year in 83.8% of the cases. Evaluating 
the variables associated with CAM use through the 
univariate analysis, we noticed that it was more popular 
among females compared with males (56.9 and 44.5%, 
p= 0.01), and older patients, ≥ 70 years of age, compared 
with younger, 40-70, (54.6 and 42.4%, p< 0.001). Also, a 
medium-high educational level seemed more frequently 
associated with CAM use compared to a low one (74.2 
vs. 25.8%, p < 0.001). Looking at the primary disease, it 
appeared that patients with a more aggressive malignancy, 
in particular lung cancer, use CAM more frequently 
compared to the others; furthermore, CAM was resulted 
more popular among subjects receiving AC alone [139 
patients (60.7%)] rather than other treatment modalities. 
Other characteristics associated with CAM use include 
anxiety disorders, lack of chronic pain, and metastatic 
disease (Table 4). Of note is that there was no difference in 
terms of CAM use based on trust in conventional medicine 
and oncological treatments and based on the personal 
awareness about the disease (Table 5). Considering the 
228 patients who did use a CAM: only the 3.9% declared 
that they had experienced side effects from such therapies 
[9 patients had diarrhea (G2) during concomitant use of 
AC and aloe]; 63.1%, on the basis of his/her personal 
experience do trust these medications; 82% think that the 
favorable response achieved is due to both the AC and 
the CAM used; 86.8% admit to having spent between 100 
and 300 euros monthly on the chosen CAM. Finally, the 
multivariate analysis indicated that the only factors which 
were confirmed to be significantly associated with the 
use of CAM were a high educational level (Odds Ratio, 
OR: 1.96 95% Confidence Interval, CI, 1.27-3.05) and 
receiving treatment in a specialized cancer center rather 
than in a peripheral hospital/clinic (OR: 2.75 95% CI, 
1.53-4.94) (Table 6).
DISCUSSION
Current international research suggests that 29-91% 
of cancer patients seek CAM in addition to anticancer 
therapies [16–23]. Our study demonstrates that CAM use 
among cancer patients in Italy is fairly widespread, with 
nearly half of those interviewed (48.9%) reporting an 
ongoing or recent use of CAM. Patients suffering from 
cancer are more likely to use CAM at some point in their 
disease history however, many available publications 
show that unconventional medicine is routinely used by 
many other categories of patients: the average lifetime 
prevalence for UK patients reported by Posadzky P et al. 
[7] is 51.8%; another work published in 2015 [16] 
analyzing the data from 263 questionnaires completed by 
New Mexican patients attending outpatient clinics for 
different diseases (heart failure, HIV, hepatitis, etc.), found 
a 56% incidence of CAM use with a significantly higher 
rate among females with a high educational level, who 
declared that they use CAM for general wellness and 
disease prevention. The study by Zhang Y et al. evaluating 
a large population of adults in the US (34.525) also 
concluded that CAM use was more popular among 
females with a higher educational level; in that work, the 
main problems leading to CAM were back pain, arthralgia, 
and migraine [24]. Looking at the literature about the 
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Table 2: General feeling about conventional medicine and CAM
General feeling about Conventional medicine and CAM n=468
AWARENESS ABOUT DISEASE n (%)
 Absent/poor 47 (10)
 Good/excellent 421 (90)
AWARENESS ABOUT TREATMENTS RECEIVED  
 Absent/poor 28 (6)
 Good/excellent 440 (94)
TRUST IN CONVENTIONAL MEDICINE  
 Yes 441 (94.2)
 No 27 (5.8)
TRUST IN ONCOLOGICAL TREATMENTS  
 Yes 445 (95)
 No 23 (5)
EXPECTATIONS FROM THE ONCOLOGICAL 
TREATMENT  
 To be treated 236 (50.4)
 To be cured 179 (38.2)
 To achieve disease stabilization 53 (11.4)
FINANCIAL SPECULATION AROUND 
ONCOLOGICAL TREATMENTS  
 Yes 150 (32)
 No 318 (68)
AWARENESS ABOUT CAM  
 Yes 354 (75.6)
 No 114 (24.4)
DIFFERENCE BETWEEN ALTERNATIVE AND 
COMPLEMENTARY MEDICINE  
 Yes 129 (27.6)
 No 339 (72.4)
SOURCE OF KNOLEDGE ABOUT CAM (n= 354)  
 Media 169 (47.7)
 Friends 68 (19.2)
 Other 54 (15.3)
 Patients 42 (11.9)
 Doctors 21 (5.9)
WHAT CAM ARE (n= 354)  
 Used to reduce the AC toxicities 108 (30.5)
 Supplements 50 (14.1)
 Anticancer treatments 29 (8.2)
 Used to increase the chances of be cured 28 (7.9)
 Overall 139 (39.3)
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oncological population, our findings suggest a higher rate 
of use compared to previous European studies, which 
appears close to the prevalence data observed in several 
US studies. Maggiore RJ et al. presented the results of a 
secondary cross sectional analysis that examined 
medication use in 545 ambulatory senior adults in the 
context of a multicenter, longitudinal study evaluating the 
utility of a comprehensive geriatric assessment in 
predicting AC toxicity among a cohort of older adults with 
cancer [12]. As part of the study, the patients were asked 
to list all their medications, including herbal preparations, 
vitamins and supplements; the mean age of the cohort was 
73 years with 52% being women; the reported CAM 
prevalence was 17%, with a mean of two herbal 
medications (range, 1–10), CAM use was shown to be 
more common among those who had an earlier cancer 
stage (i.e., those receiving adjuvant, potentially curative 
treatment, OR 2.05; 95% CI, 1.21-3.49) and higher 
functional status (less impairment with instrumental 
activities of daily living, OR 1.39; 95% CI, 1.12-1.73), no 
difference was noticed between males and females. In an 
abstract presented by Lichtman SM et al. [13] at ASCO 
2009, the prevalence of herbal/vitamin use was 46% in a 
cohort of 154 cancer patients aged ≥ 65 years of age, no 
information were given about potential association 
between CAM use and sex, educational level and/or 
cancer stage. In a retrospective study by Sokol KC et al. 
[14], considering 100 ambulatory senior adults with cancer 
(mean age 78 years, range: 70–90), the reported rate of 
CAM use was 46%, slightly lower compared to to our 
finding. Wyatt GK et al. [15] reported the data of a survey 
carried out among 699 cancer patients who were receiving 
AC, 33% declared that they use complementary therapies. 
The characteristics associated with CAM use were: being 
female, having breast cancer and high level of education; 
the most frequent practices were exercise, herbal therapy, 
and spiritual healing; there were no differences with 
respect to reported depressive symptomatology or 
spirituality. Nightingale G et al. [25] explored the 
prevalence of CAM and factors influencing CAM use in a 
secondary analysis of 248 senior adults with cancer (mean 
age 79.9) who received an initial comprehensive geriatric 
oncology assessment; 234 subjects were included in the 
final analysis. In that study, the prevalence of CAM use 
was much lower compared to our finding, 26.5%; 
polypharmacy, vision impairment and urologic 
comorbidities were found associated with CAM use. Such 
a difference in terms of prevalence of CAM use is in part 
justified by the direct involvement of a clinical pharmacist 
who went through the complete list of medications of each 
patient and actively helped to define what CAM was; also, 
vitamins were excluded. In regards to patient 
demographics, a higher rate of CAM use was observed in 
women (19% vs. 8%) though the population was not well 
balanced (64% females, 36% males); the educational level 
was not mentioned. An interesting study involving 294 
prostate cancer patients reported a 25% rate of CAM use, 
mainly vitamins, low-fat diets, lycopene and green tea. 
The multivariate analyses revealed no differences in 
mental health scores between users and non-users; users 
Figure 1: Source of knowledge about CAM.
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Table 3: Personal experience with CAM, distribution of CAM users
Personal experience with CAM n=229
REASON FOR USE n (%)
 Anticancer treatment 15 (6.6)
 Supportive care 146 (63.8)
 Other 68 (29.7)
TIME OF USE  
 Before the diagnosis of cancer 18 (7.9)
 At or after the diagnosis of cancer 211 (92.1)
DURATION OF USE  
 < 1 year 192 (83.8)
 1 - 2 years 29 (12.7)
 > 2 years 8 (3.5)
TYPE  
 Herbal preparations 59 (25.8)
 Vitamins 44 (19.2)
 Supplements 109 (47.6)
 Other CAM 17 (7.4)
PRESCRIBER  
 Auto-prescription 155 (67.7)
 Oncologist 13 (5.7)
 Other doctor 13 (5.7)
 Friend 42 (18.3)
 Relative 6 (2.6)
AWARENESS ABOUT POTENTIAL SIDE EFFECTS  
 Yes 32 (14)
 No 197 (86)
BENEFIT  
 Yes 79 (34.5)
 No 15 (6.6)
 Unsure 135 (59)
SIDE EFFECTS  
 Yes 8 (3.5)
 No 221 (96.5)
DISEASE PROGRESSION DUE TO  
 Disease itself 179 (78.2)
 CAM 2 (0.9)
 AC 6 (2.6)
 Other 42 (18.3)
(Continued )
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were younger (OR 0.93, 95% CI 0.89–0.97) and more 
likely to be receiving ‘active surveillance’ rather than 
treatment (OR 5.23, 95% CI 1.78–15.41). An important 
finding was that nearly half of the users, 43%, had not 
informed any doctor about the product taken [25]. The 
European survey published by Molassiotis A et al. [26] 
included 956 patients from fourteen countries. 
Approximately one third of the interviewed, 35.9%, said 
that they were CAM users, with a higher rate in Italy (the 
Italian data were only on 52 patients treated with palliative 
care); the three variables strongly associated with CAM 
use were female gender, younger age and a high 
educational level. An interesting survey by Patterson RE 
et al. [27] involving 356 patients with colon, breast, or 
prostate cancer identified from the Cancer Surveillance 
System of western Washington showed a prevalence of 
CAM use up to 70.2% with females five times more likely 
to see an alternative provider and about twice as likely to 
use mental therapies or supplements (p < 0.05 for all). 
Also younger age and higher education were associated 
with the use of all types of CAM; general health and well-
being were the main reasons for CAM consumption. In the 
work by Richardson et al. [28], 83.3% of the responders 
had used at least one CAM approach, use was greatest for 
spiritual practices (80.5%), vitamins and herbs (62.6%), 
and movement and physical therapies (59.2%) and was 
predicted (P <.001) by sex (female), younger age, indigent 
pay status, and surgery. Oneschuk et al. [29] (Canada) 
published their findings from 143 advanced cancer patients 
attending an outpatient pain and symptom clinic at a 
regional cancer center in which they found a 37% rate of 
CAM use: 39.6% herbs, 32.5% vitamins, 6.6% minerals, 
10.7% other medications including shark cartilage, and 
10.7% could not be identified. Both the anticancer effect 
and the promotion of well-being were prominent among 
the stated reasons for using these medications. Our study 
Personal experience with CAM n=229
DISEASE RESPONSE DUE TO  
 CAM 2 (0.9)
 AC 47 (20.5)
 Both 180 (78.6)
ONCOLOGIST INFORMED  
 Yes 196 (85.6)
 No 33 (14.4)
COST  
 < 100 euros 78 (34.1)
 100 – 300 euros 144 (62.9)
 > 300 euros 7 (3.1)
PAYED BY  
 Patient 226 (98.6)
 National Healthcare Service 3 (1.3)
CAM EVALUATION  
 Useful as AC treatment 72 (31.4)
 Useful as adjuvant treatment 131 (57.2)
 Useless 26 (11.4)
WOULD YOU RECOMMEND CAM  
 Yes 200 (87.3)
 NO 29 (12.7)
TRUST IN CAM  
 Yes 154 (67.2)
 No 12 (5.2)
 I don’t know 63 (27.5)
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Table 4: CAM use: Association with demographics and disease characteristics
Variable 
CAM use
p* 
YES n= 229(%) NO n= 239(%)
SEX    
 male 103(45) 136(56.9) 0.01
 female 126(55) 103(43.1)  
Age    
 < 40 7(3.1) 16(6.7) < 0.0001
 40 – 70 97(42.4) 148(61.9)  
 > 70 125(54.6) 75(31.4)  
EDUCATION    
  Elementary/middle 
(< 8 ys) 59(25.8) 119(49.8) < 0.0001
 High/degree (< 8 ys) 170(74.2) 120(50.2)  
ORIGIN    
 Centre/North 173(75.5) 72(30.1) < 0.0001
 South/Islands 56(24.5) 167(69.9)  
ANXIETY    
 Often 25(10.9) 47(19.7) < 0.0001
 Sometimes 29(12.7) 53(22.2)  
 Never 175(76.4) 139(58.2)  
PAIN    
 Yes 93(40.6) 57(23.8) < 0.0001
 No 136(59.4) 182(76.2)  
HOSPITAL    
 Cancer centre 202(88.2) 123(51.5) < 0.0001
 Peripheral hospital/clinic 27(11.8) 116(48.5)  
PRIMARY TUMOUR    
 Breast 24(10.5) 54(22.6) < 0.0001
 Lung 164(71.6) 58(24.3)  
 Colorectal 11(4.8) 45(18.8)  
 Gastr/Pancr/HCC/Bil tract 5(2.2) 18(7.5)  
 Uro-Gynecology 6(2.6) 20(8.4)  
 Other 19(8.3) 44(18.4)  
STAGE AT DIAGNOSIS    
 Early 29 (12.7) 71 (29.7) <0.0001
 Locally advanced 47 (20.5) 67 (28)  
 Metastatic 153 (66.8) 101 (42.3)  
TREATMENT    
 Surgery only 4(1.7) 21(8.8) < 0.0001
 AC only 139(60.7) 99(41.4)  
 Surgery +AC 12(5.2) 39(16.3)  
 Multimodal 74(32.3) 80(33.5)  
PS    
 0 1(0.4) 52(21.8) < 0.0001
 1-2 206(90) 140(58.6)  
 > 2 22(9.6) 47(19.7)  
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Table 5: CAM use: Association with awareness about disease and trust in conventional medicine
Variables 
CAM use
p* 
YES n= 229(%) NO n= 239(%)
AWARENESS ABOUT 
DISEASE    
 Absent/poor 26(11.4) 21(8.8) 0.4
 Good/excellent 203(88.6) 218(91.2)  
AWARENESS ABOUT 
TREATMENTS    
 Absent/poor 8(3.5) 2088.4) 0.026
 Good/excellent 221(96.5) 219(91.6)  
EXPECTATIONS FROM 
ONCOL. TREATM.    
 To be treated 161 (70.3) 75 (31.4) <0.0001
 To be cured 43 (18.8) 136 (56.9)  
  To achieve disease 
stabilization
25 (10.9) 28 (11.7)  
TRUST IN 
CONVENTIONAL 
MEDICINE
   
 Yes 218(95.2) 223(93.3) 0.4
 No 11(4.8) 16(6.7)  
TRUST IN 
ONCOLOGICAL 
TREATMENTS
   
 Yes 216 (94.3) 229 (95.8) 0.4
 No 13 (5.7) 10 (4.2)  
FINANCIAL SPEC. 
AROUND ONC. 
TREATM.
   
 Yes 44 (19.2) 60 (25.1) 0.009
 No 170 (74.2) 148 (61.9)  
 Don’t know 15 (6.6) 31 (13)  
SOURCE OF 
KNOWLEDGE ABOUT 
CAM
   
 Media 133(58.1) 36(28.8) < 0.0001
 Doctors 9(3.9) 12(9.6)  
 Patients 18(7.9) 24(19.2)  
 Friends 45(19.7) 23(18.4)  
 Other 24(10.5) 30(24)  
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has corroborated some findings already observed in 
previous papers. Firstly, the higher prevalence of CAM 
use among females and, in general, in the subset of 
patients with a high educational level. Probably a high 
education level allows easier access to the media, internet 
and information about medicine. An aspect that has 
emerged in our dataset is the higher rate of CAM use in 
patients receiving their treatment in highly-specialized 
cancer centers rather than in peripheral hospitals/clinics. 
In the univariate analysis we also found that patients with 
anxiety disorders were more likely to use CAM though 
this association was not confirmed by the multivariate 
analysis; however, this lack of statistical significance may 
be due to the low number of patients suffering from 
anxiety present in our study (only 15.4%, 72/368). Our 
data are also consistent with the available literature 
regarding the absence of a relationship between CAM use 
and lack of trust in conventional medicine, other authors, 
in fact, have already observed that CAM are often used by 
patients who are fully satisfied with conventional health 
care and look for adjuvants rather than for substitutes to 
traditional practices [29, 30]. As observed in previous 
studies [31–34] supplements and herbal medications are 
the main CAM used by cancer patients and they are more 
likely to be used as adjuvants, to reduce AC side effects, 
rather than as direct anticancer treatments. In contrast with 
prior observations, 85% of our interviewed subjects said 
that they had informed their oncologist about their CAM 
use, though such data should be carefully interpreted due 
to the administration of our questionnaire by physicians. 
The costs sustained to buy CAM were between 100 and 
300 euros per patient, per month for most patients (62.9%) 
and were paid for by the patients themselves in 98.6% of 
cases. Such finding is consistent with the estimated cost 
per year of supplements in Italy which accounts up to 2.5 
billion of euros [35]. The most CAM used was aloe (75% 
of patients). In 67.7% of the cases, the CAM prescription 
was a self-prescription and only in 11.4% of the cases had 
a doctor prescribed the CAM. This aspect is very 
dangerous considering the risk of toxicities and potential 
interaction between CAM and standard/conventional 
medicine; regarding this aspect, 197 patients (86%) did 
not know about the risk of potential side effects. Finally, 
the high rate of satisfaction from CAM and the fact that 
approximately all the users (87%) recommended their use, 
indeed, deserves attention; maybe healthcare professionals 
in general and oncologists in particular should pay more 
attention to this aspect of the anamnesis at the time of the 
visit and check at each control, especially for patients on 
AC, if new conventional or unconventional drugs have 
been added to the patient’s personal therapy. The routine 
anamnesis collection should be completed by explicit 
questions about the use of herbals, supplements, and any 
other preparations. In fact some CAM products can 
interfere with some AC through effects on the metabolic 
pathway and oncologists must be careful to avoid drug-
herbs interaction when they plan a treatment with herbal 
medications as supplement to AC (Table 7).
The use of CAM in oncologic patients is a growing 
issue that requires more attention by the scientific world 
and physicians. To know the causes that induce oncologic 
patients to inappropriately use CAM is of fundamental 
importance. To retrieve the distortion of the information 
sources and to improve the communication modalities 
are crucial steps to preserve the health of patients, trough 
the strengthening of the therapeutics alliance and of the 
adhesion to treatment with reliable efficacy. We firmly 
believe that to promote knowledge about CAM between 
patients and physicians with the aim of alerting them to 
potential toxicities is very important. The need to increase 
the evidence base of CAM therapies, using methodologies 
that are appropriate and sensitive to CAM cannot be 
overemphasized. This is also important from an economic 
point of view, as its use is a multibillion Euro business, 
Table 6: Multivariate analysis: High education and receiving treatment in a specialized cancer center are associated 
with higher risk of CAM use
  CAM users  
OR (95% CI)* p-value
EDUCATION   
  0.003
 Elementary/middle (< 8 ys) 1.0†  
 High/degree (< 8 ys) 1.96 (1.27-3.05)  
HOSPITAL   
  0.001
Peripheral hospital/clinic 1.0†  
Cancer centre 2.75 (1.53-4.94)  
* Logistic regression analysis adjusted by terms of gender, age, centre, education when appropriate;† Reference category.
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and, as shown in this study, some patients pay large sums 
out of their pockets to receive such interventions. In the 
US, where such data are available, the use of CAM is 
conservatively estimated to cost patients US$ 27 billion 
(for the year 1997) [36]. In the EU it is the second biggest 
growth industry [37]. Finally, appropriate legislation and 
regulation of CAM therapies in the EU is also necessary.
MATERIALS AND METHODS
Patients setting
A cross-sectional descriptive survey design was used 
to collect data trough a questionnaire about CAM therapies. 
Nine hospitals with oncology and/or radiotherapy divisions 
were approached for possible collaboration in this study. Of 
the nine hospitals, five agreed to participate. A key person 
from each hospital was selected, based on interest in and/
or experience with CAM. Data collected from each hospital 
were returned to one of the investigators and then the data 
were coded for analysis. This survey was approved by the 
ethics committees and carried out between September 2014 
and May 2015. Both metastatic and non-metastatic cancer 
patients were included from cancer hospitals, oncology units 
of general hospitals, day units, and radiotherapy units. All 
participating patients received information about the study. 
Patients were considered eligible if they met the following 
inclusion criteria, they were Italian-speaking, adult patients 
of either gender with a diagnosis of cancer; aware of their 
diagnosis; were receiving an anticancer treatment [antiblastic 
chemotherapy (AC), endocrine therapy, radiotherapy 
and surgery] at the time of the survey or had received an 
anticancer treatment no more than three years before 
participating in the survey; able to understand the questions; 
free from any condition that would make completing 
the questionnaire inappropriate or overburdening for the 
patients; and they were willing to participate in the study.
Procedures
The questionnaire was administered to the 
patients after they received information about the study, 
agreed to participate, and signed the consent form. 
Patients completed the questionnaire with the support 
of a physician. Participation was voluntary and did not 
interfere with medical treatment.
The questionnaire
The questionnaire used was based on the one 
developed by Molassiotis A et al. [26]. However, the 
questionnaire was modified for the purpose of the present 
study and some new items were added (for example: 
awareness about the disease and treatment received, trust 
in conventional medicine and oncological treatments, 
Table 7: The most common botanicals used in cancer patients and their possible interactions with drugs [39–43]
Agents Effect on metabolic pathway Interaction with anticancer drugs
Ananas (Bromeline) CYP2C9 inhibition Risk of over dosage with paclitaxel
Curcuma CYP1A2, CYP2B6, CYP2C9, 
CYP2D6 weak inhibition
Risk of over Dosage with Bendamustine, Risk of inefficacy 
of pro-drugs (Ciclophosphamide, Tamoxifen etc)
Cannabinoides CYP2C9 induction Risk of over dosage of prodrugs (Ciclophosphamide, Tamoxifen etc)
Echinacea CYP3A4 induction
Improved pharmacokinetic (weak) of Ciclophosphamide 
dasatinib, docetaxel, erlotinib, imatinib, sorafenib, vinca 
alkaloides
ESSIAC* CYP3A4 inhibition Risk of over Dosage with bortezomib, dasatinib, docetaxel, erlotinib, imatinib, sorafenib, vinca alkaloides
Green Tea CYP3A4 inhibition As for Essiac
Gingko Biloba CYP3A4 CYP2C19, inhibition As for Essiac
Grape Fruit CYP3A4 inhibition As for Essiac
Licorice CYP2B6, CYP3A4 weak inhibition As for Essiac (weak)
milk thistle CYP2C8, CYP2C9 weak inhibition Risk of over Dosage with ciclophosphamide, paclitaxel
St. John’s worth 
(Hypericum) CYP3A4 induction
Improved pharmacokinetic of Ciclophosphamide dasatinib, 
docetaxel, erlotinib, imatinib, sorafenib, vinca alkaloides
Additional Source: http://reference.medscape.com/drug-interactionchecker.
Abbreviations: Cytochrome P450: CYP.
*Essiac: herbal mixture patented as anticancer therapy in the 1920 by Rene Caisse in Canada.
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expectations from oncological treatments, awareness about 
CAM, knowledge about the differences between alternative 
and complementary medicine, source of knowledge about 
CAM and role of CAM in oncological treatment), and some 
others were modified to reflect Italian culture (for example: 
geographic area of origin) there were 42 items in total. These 
included demographic data (age, gender, occupation, and 
education), clinical data (site of primary cancer, standard 
treatments received previously and current standard 
treatment) and questions about CAM use, in particular: 
knowledge about what CAM is and whether it has ever 
been used. The questionnaire about CAM was completed 
only by the patients who declare that they have had, or had 
at the time of the survey, a personal experience with CAM 
and included eighteen questions about different aspects of 
such therapies concerning, e.g. efficacy, cost, side effects, 
satisfaction rating. On the basis of the available literature 
we decided to exclude from the analysis medical therapies 
routinely prescribed, such as iron, vitamin D, and calcium 
supplements, which are often used as support therapy.
Data analysis
In the descriptive analysis, the median, range, and 
relative frequencies were used. Analyses of frequencies 
and cross tables with χ2 tests were done using IBM SPSS 
Statistics 20 [38]. In this study, we focused on those 
questions that were the same or similar in both group 
in order to compare patients and professionals. Only 
completely filled-out questionnaires were analyzed.
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